Review ArticleReview Article
Open Access
The Nitrogen Mustards
Martin S. Highley, Bart Landuyt, Hans Prenen, Peter G. Harper and Ernst A. De Bruijn
Michael Gottesman, ASSOCIATE EDITOR
Pharmacological Reviews July 2022, 74 (3) 552-599; DOI: https://doi.org/10.1124/pharmrev.120.000121
Martin S. Highley
Plymouth Oncology Centre, Derriford Hospital, and Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom (M.S.H.); Department of Animal Physiology and Neurobiology (B.L.) and Laboratory for Experimental Oncology (E.A.D.B.), University of Leuven, Leuven, Belgium; Oncology Department, University Hospital Antwerp, Edegem, Belgium (H.P.); and London Oncology Clinic, London, United Kingdom (P.G.H.)
Bart Landuyt
Plymouth Oncology Centre, Derriford Hospital, and Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom (M.S.H.); Department of Animal Physiology and Neurobiology (B.L.) and Laboratory for Experimental Oncology (E.A.D.B.), University of Leuven, Leuven, Belgium; Oncology Department, University Hospital Antwerp, Edegem, Belgium (H.P.); and London Oncology Clinic, London, United Kingdom (P.G.H.)
Hans Prenen
Plymouth Oncology Centre, Derriford Hospital, and Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom (M.S.H.); Department of Animal Physiology and Neurobiology (B.L.) and Laboratory for Experimental Oncology (E.A.D.B.), University of Leuven, Leuven, Belgium; Oncology Department, University Hospital Antwerp, Edegem, Belgium (H.P.); and London Oncology Clinic, London, United Kingdom (P.G.H.)
Peter G. Harper
Plymouth Oncology Centre, Derriford Hospital, and Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom (M.S.H.); Department of Animal Physiology and Neurobiology (B.L.) and Laboratory for Experimental Oncology (E.A.D.B.), University of Leuven, Leuven, Belgium; Oncology Department, University Hospital Antwerp, Edegem, Belgium (H.P.); and London Oncology Clinic, London, United Kingdom (P.G.H.)
Ernst A. De Bruijn
Plymouth Oncology Centre, Derriford Hospital, and Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom (M.S.H.); Department of Animal Physiology and Neurobiology (B.L.) and Laboratory for Experimental Oncology (E.A.D.B.), University of Leuven, Leuven, Belgium; Oncology Department, University Hospital Antwerp, Edegem, Belgium (H.P.); and London Oncology Clinic, London, United Kingdom (P.G.H.)
Michael Gottesman
Roles: ASSOCIATE EDITOR
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Review ArticleReview Article
The Nitrogen Mustards
Martin S. Highley, Bart Landuyt, Hans Prenen, Peter G. Harper and Ernst A. De Bruijn
Pharmacological Reviews July 1, 2022, 74 (3) 552-599; DOI: https://doi.org/10.1124/pharmrev.120.000121
Jump to section
- Article
- Abstract
- I. Introduction
- II. Molecular Chemistry and Pharmacology
- III. Immunomodulatory Activity
- IV. Analytical Chemistry
- V. Preclinical Pharmacology
- VI. Clinical Pharmacology
- VII. The Clinical Use of the Nitrogen Mustards
- VIII. Metronomic Scheduling
- IX. Novel Nitrogen Mustard Derivatives and Targeted Delivery Approaches
- X. Nitrogen Mustard Combinations with Monoclonal Antibodies and Small-Molecule Targeted Agents
- XI. Cyclophosphamide in Combination with Vaccine Therapy and Virotherapy
- XII. Conclusions
- XIII. Perspectives
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement